[{"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-001", "question": "A 58-year-old man undergoes pancreaticoduodenectomy for a 2.5 cm pancreatic head adenocarcinoma. On postoperative day 3, his closed-suction drain has serous output of 25 mL/24 hours. Drain fluid amylase is 1,200 U/L (serum amylase 150 U/L). He is afebrile, hemodynamically stable, with soft abdomen and no leukocytosis. What is the most appropriate next step in management?", "options": ["Remove the drain", "Keep the drain and start octreotide", "Obtain contrast-enhanced CT of abdomen", "Keep the drain and discharge to home", "Return to operating room for exploration"], "answer": "A", "answer_index": 0, "explanation": "The 2016 ISGPS update defines a 'biochemical leak' as drain fluid amylase >3x serum on POD 1-3 with output <30 mL/day and no clinical sequelae, which can be managed by drain removal. Grade B fistula requires output >30 mL/day or clinical impact. The high amylase alone does not mandate retention if output remains low and the patient is clinically well.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient on POD 3 after a Whipple procedure with a 'Biochemical Leak' (formerly Grade A fistula): elevated drain amylase (>3x serum) but low volume (25 mL) and no clinical symptoms. Modern pancreatic surgery guidelines (ISGPS 2016) and Enhanced Recovery After Surgery (ERAS) protocols support drain removal in this scenario. The low volume (<30–50 mL/day) indicates the leak is minor and the peritoneum can absorb the fluid; keeping the drain increases the risk of retrograde infection. Option A is the correct management. Option D is incorrect because discharging a Whipple patient on POD 3 is clinically unsafe/unrealistic regardless of drain status. Option B (Octreotide) is not indicated for asymptomatic biochemical leaks. Option C is unnecessary in a stable, afebrile patient. The item is medically accurate and logically sound, testing a specific, high-yield management decision.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient on POD 3 after a Whipple procedure with a 'Biochemical Leak' (formerly Grade A fistula): elevated drain amylase (>3x serum) but low volume (25 mL) and no clinical symptoms. Modern pancreatic surgery guidelines (ISGPS 2016) and Enhanced Recovery After Surgery (ERAS) protocols support drain removal in this scenario. The low volume (<30–50 mL/day) indicates the leak is minor and the peritoneum can absorb the fluid; keeping the drain increases the risk of retrograde infection. Option A is the correct management. Option D is incorrect because discharging a Whipple patient on POD 3 is clinically unsafe/unrealistic regardless of drain status. Option B (Octreotide) is not indicated for asymptomatic biochemical leaks. Option C is unnecessary in a stable, afebrile patient. The item is medically accurate and logically sound, testing a specific, high-yield management decision.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-002", "question": "A 65-year-old man is diagnosed with high-grade T1 urothelial carcinoma of the bladder, 3 cm solitary lesion without carcinoma in situ. His EORTC risk score is 8. He is scheduled to begin intravesical BCG immunotherapy. What is the optimal evidence-based regimen?", "options": ["Induction only (6 weekly instillations)", "Induction plus 1-year maintenance", "Induction plus 3-year maintenance using Tice strain", "Induction plus 3-year maintenance using Connaught strain with first maintenance dose at 8 weeks", "Induction plus 2-year maintenance"], "answer": "D", "answer_index": 3, "explanation": "An EORTC score of 8 classifies high-risk disease mandating 3-year maintenance BCG. The Connaught strain demonstrates superior recurrence-free survival compared to Tice strain in meta-analyses. Maintenance must commence 8 weeks after induction completion. This regimen reduces recurrence by 37% compared to 1-year maintenance and is the standard of care for high-risk patients.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Miskeyed / Not uniquely determinable\\n\\nThe clinical vignette describes a patient with high-risk non-muscle-invasive bladder cancer (T1, high grade, >3cm). Current guidelines (AUA, EAU) recommend induction BCG followed by 3 years of maintenance therapy. Both Options C and D describe this correct duration. The question attempts to discriminate based on BCG strain (Connaught vs. Tice), claiming Connaught is 'optimal' based on specific meta-analyses. However, major guidelines state that strain choice should be determined by availability, noting that efficacy data between strains is conflicting or insufficient to mandate one over the other. Furthermore, the Connaught strain has faced significant global shortages and discontinuation in major markets (e.g., USA), making Tice the standard of care by necessity in many regions. Therefore, Option C (Tice) is a fully defensible, standard-of-care answer. Additionally, the phrasing 'at 8 weeks' in Option D is ambiguous (referring to calendar week 8 vs. an 8-week interval post-induction). Because the strain distinction is not a universally accepted board-level discriminator and Tice is a valid standard, the item has multiple correct answers.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Miskeyed / Not uniquely determinable\n\nThe clinical vignette describes a patient with high-risk non-muscle-invasive bladder cancer (T1, high grade, >3cm). Current guidelines (AUA, EAU) recommend induction BCG followed by 3 years of maintenance therapy. Both Options C and D describe this correct duration. The question attempts to discriminate based on BCG strain (Connaught vs. Tice), claiming Connaught is 'optimal' based on specific meta-analyses. However, major guidelines state that strain choice should be determined by availability, noting that efficacy data between strains is conflicting or insufficient to mandate one over the other. Furthermore, the Connaught strain has faced significant global shortages and discontinuation in major markets (e.g., USA), making Tice the standard of care by necessity in many regions. Therefore, Option C (Tice) is a fully defensible, standard-of-care answer. Additionally, the phrasing 'at 8 weeks' in Option D is ambiguous (referring to calendar week 8 vs. an 8-week interval post-induction). Because the strain distinction is not a universally accepted board-level discriminator and Tice is a valid standard, the item has multiple correct answers.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with Grade 3 immune-mediated colitis (6 stools/day) and concurrent immune-mediated hepatitis. Although the rationale describes the hepatitis as Grade 2, the ALT of 220 U/L (with ULN 40) is 5.5x ULN, which technically meets CTCAE criteria for Grade 3 (>5.0–20.0x ULN). Regardless of this minor grading discrepancy, the presence of significant transaminitis makes infliximab (Option A) inappropriate due to the risk of hepatotoxicity. Current guidelines (ASCO/NCCN/SITC) recommend high-dose corticosteroids (prednisone 1–2 mg/kg) as the first-line treatment for Grade 3 colitis. Biologics like vedolizumab or infliximab are reserved for steroid-refractory cases (typically assessed after 48–72 hours). Vedolizumab is the preferred biologic in this scenario due to its gut-selectivity and lack of hepatotoxicity. Therefore, Option C correctly identifies the stepwise management: start steroids and add vedolizumab only if there is no improvement. Option B is incorrect because upfront combination therapy is not standard. Option D is unsafe for Grade 3 toxicity. Option E is not the correct first-line intervention for symptomatic colitis. The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with Grade 3 immune-mediated colitis (6 stools/day) and concurrent immune-mediated hepatitis. Although the rationale describes the hepatitis as Grade 2, the ALT of 220 U/L (with ULN 40) is 5.5x ULN, which technically meets CTCAE criteria for Grade 3 (>5.0–20.0x ULN). Regardless of this minor grading discrepancy, the presence of significant transaminitis makes infliximab (Option A) inappropriate due to the risk of hepatotoxicity. Current guidelines (ASCO/NCCN/SITC) recommend high-dose corticosteroids (prednisone 1–2 mg/kg) as the first-line treatment for Grade 3 colitis. Biologics like vedolizumab or infliximab are reserved for steroid-refractory cases (typically assessed after 48–72 hours). Vedolizumab is the preferred biologic in this scenario due to its gut-selectivity and lack of hepatotoxicity. Therefore, Option C correctly identifies the stepwise management: start steroids and add vedolizumab only if there is no improvement. Option B is incorrect because upfront combination therapy is not standard. Option D is unsafe for Grade 3 toxicity. Option E is not the correct first-line intervention for symptomatic colitis. The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-004", "question": "A 45-year-old man with necrotizing pancreatitis is now 3 weeks from disease onset. Contrast-enhanced CT demonstrates a 9-cm walled-off necrosis in the lesser sac with a mature, well-defined wall. ERCP confirms disconnected pancreatic duct syndrome. He is febrile to 38.5°C with WBC 15,000 cells/µL. What is the definitive management?", "options": ["Immediate percutaneous catheter drainage", "Endoscopic ultrasound-guided cystgastrostomy now", "Surgical cystgastrostomy with necrosectomy now", "Delay intervention until 4 weeks then proceed endoscopically", "Continue antibiotics and observe"], "answer": "C", "answer_index": 2, "explanation": "The 2020 revised Atlanta guidelines permit intervention when WON demonstrates a mature wall, eliminating the mandatory 4-week wait. Disconnected pancreatic duct syndrome is a surgical indication because endoscopic drainage alone is associated with 40% recurrence. Surgical cystgastrostomy with necrosectomy definitively addresses both the necrosis and ductal disruption, reducing recurrence to <10%.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a patient with infected walled-off necrosis (WON) and disconnected pancreatic duct syndrome (DPDS). The stem states the wall is mature at 3 weeks, allowing for internal drainage. The key (C) advocates for immediate surgical cystgastrostomy with necrosectomy. However, current high-quality evidence (PANTER, TENSION, PENGUIN trials) and major guidelines (ACG, AGA) establish the 'endoscopic step-up approach' as the standard of care. Endoscopic ultrasound-guided drainage (Option B) is preferred over surgery due to lower morbidity, shorter hospital stays, and equal efficacy. For DPDS, endoscopic placement of long-term transmural plastic stents is a well-accepted definitive strategy. Primary open surgery is generally reserved for patients who fail endoscopic approaches. Additionally, the rationale cites '2020 revised Atlanta guidelines' (the actual revision was 2012) and relies on a surgical bias that contradicts modern consensus. Since Option B represents the current standard of care while the key is Option C, the item is miskeyed.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a patient with infected walled-off necrosis (WON) and disconnected pancreatic duct syndrome (DPDS). The stem states the wall is mature at 3 weeks, allowing for internal drainage. The key (C) advocates for immediate surgical cystgastrostomy with necrosectomy. However, current high-quality evidence (PANTER, TENSION, PENGUIN trials) and major guidelines (ACG, AGA) establish the 'endoscopic step-up approach' as the standard of care. Endoscopic ultrasound-guided drainage (Option B) is preferred over surgery due to lower morbidity, shorter hospital stays, and equal efficacy. For DPDS, endoscopic placement of long-term transmural plastic stents is a well-accepted definitive strategy. Primary open surgery is generally reserved for patients who fail endoscopic approaches. Additionally, the rationale cites '2020 revised Atlanta guidelines' (the actual revision was 2012) and relies on a surgical bias that contradicts modern consensus. Since Option B represents the current standard of care while the key is Option C, the item is miskeyed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a classic case of biopsy-proven BK virus nephropathy (BKVN). The standard management is the reduction of immunosuppression. While guidelines (e.g., AST ID COP) list both antimetabolite reduction and CNI reduction as valid strategies, the specific options allow for the identification of a single best answer. Option B (reduce MMF by 50%) is the most widely accepted 'first' step in many protocols to balance viral clearance with rejection risk, preserving the CNI backbone. Crucially, Option A suggests reducing the tacrolimus dose by 50%; with a current trough of 8 ng/mL, a 50% dose cut would likely precipitate subtherapeutic levels (<4–5 ng/mL) and significant rejection risk, making it inferior to B. Option D (stopping MMF) is a valid strategy but often reserved for higher viral loads or failure of partial reduction. Thus, B is the safest and most standard initial modification among the choices. The item is logically valid and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a classic case of biopsy-proven BK virus nephropathy (BKVN). The standard management is the reduction of immunosuppression. While guidelines (e.g., AST ID COP) list both antimetabolite reduction and CNI reduction as valid strategies, the specific options allow for the identification of a single best answer. Option B (reduce MMF by 50%) is the most widely accepted 'first' step in many protocols to balance viral clearance with rejection risk, preserving the CNI backbone. Crucially, Option A suggests reducing the tacrolimus dose by 50%; with a current trough of 8 ng/mL, a 50% dose cut would likely precipitate subtherapeutic levels (<4–5 ng/mL) and significant rejection risk, making it inferior to B. Option D (stopping MMF) is a valid strategy but often reserved for higher viral loads or failure of partial reduction. Thus, B is the safest and most standard initial modification among the choices. The item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-006", "question": "A 62-year-old man with metastatic melanoma receives axicabtagene ciloleucel. On day 7 post-infusion, he develops confusion, expressive aphasia, and asterixis. He has a low-grade fever (37.8°C) only. ICE score is 8/10. EEG demonstrates triphasic waves. Brain MRI is normal. What is the immediate management?", "options": ["Tocilizumab 8 mg/kg intravenously once", "Dexamethasone 10 mg intravenously every 6 hours", "Methylprednisolone 1 g intravenously daily", "Tocilizumab plus dexamethasone 10 mg every 6 hours", "Supportive care with scheduled haloperidol"], "answer": "B", "answer_index": 1, "explanation": "An ICE score of 8 indicates grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS), which requires dexamethasone 10 mg IV q6h. Tocilizumab is indicated for cytokine release syndrome (CRS), not ICANS, and is unnecessary for grade 1 CRS. High-dose methylprednisolone is reserved for grade ≥3 ICANS. The EEG findings are characteristic but do not escalate management beyond standard ICANS algorithms.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item contains significant medical inaccuracies but remains logically solvable via elimination. First, axicabtagene ciloleucel (Axi-cel) is indicated for B-cell lymphomas, not melanoma (which lacks the CD19 target), making the clinical premise factually impossible. Second, the provided rationale incorrectly classifies an ICE score of 8 as Grade 2 ICANS; per ASTCT consensus, ICE 7–9 defines Grade 1. Standard management for Grade 1 is typically supportive care/observation, whereas Grade 2 requires dexamethasone. However, for Axi-cel specifically, early steroid intervention (Option B) is sometimes considered even in Grade 1 due to high progression risk. Crucially, Option E is contraindicated because haloperidol lowers the seizure threshold in a patient with neurotoxicity (indicated by triphasic waves). Options A and D are incorrect as tocilizumab is for CRS (absent here, temp <38°C). Option C is for higher grades. Thus, Option B is the only defensible best answer, despite the author's errors regarding the cancer indication and ICANS grading definitions.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item contains significant medical inaccuracies but remains logically solvable via elimination. First, axicabtagene ciloleucel (Axi-cel) is indicated for B-cell lymphomas, not melanoma (which lacks the CD19 target), making the clinical premise factually impossible. Second, the provided rationale incorrectly classifies an ICE score of 8 as Grade 2 ICANS; per ASTCT consensus, ICE 7–9 defines Grade 1. Standard management for Grade 1 is typically supportive care/observation, whereas Grade 2 requires dexamethasone. However, for Axi-cel specifically, early steroid intervention (Option B) is sometimes considered even in Grade 1 due to high progression risk. Crucially, Option E is contraindicated because haloperidol lowers the seizure threshold in a patient with neurotoxicity (indicated by triphasic waves). Options A and D are incorrect as tocilizumab is for CRS (absent here, temp <38°C). Option C is for higher grades. Thus, Option B is the only defensible best answer, despite the author's errors regarding the cancer indication and ICANS grading definitions.", "medical_accuracy_score": 2, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 2}]